System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Laurent Misery is an expert in Dermatology at Centre Hospitalier Régional Universitaire de Brest (France). As of October 2026, ScienceLeadR ranks Laurent Misery in the top 1% of experts worldwide for Pruritus, Prurigo and Sexually Transmitted Diseases. Laurent Misery has authored 1,189 publications, the most recent in 2026, and is an investigator in 41 clinical trials, 14 of them ongoing. SLR score: 4,020 (community average: 125). How the SLR is computed.

LeadR Profile

Laurent Misery Centre Hospitalier Régional Universitaire de Brest France
4 020 ScienceLeadR Reputation 4020

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Public Health - Immunology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026
Source: PubMed

Centre Hospitalier Régional Universitaire de Brest

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1189

Citations

Citations: 21 827 1st author: 153 Last author: 320 Unique author: 88

Main journals

Ann Dermatol Venereol 327
J Eur Acad Dermatol Venereol 117
Acta Derm Venereol 67
Br J Dermatol 56
Annales de dermatologie et de vénéréologie, FMC 50

Best Journals

N Engl J Med 3
BMJ 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Assessing coping, loneliness, resilience and partner burden in patients with skin conditions: protocol for a multicentre cross-sectional study across 23 dermatology centres in 15 European countries.
PMID 42907126 — loneliness, skin, cross-sectional studies, dermatology		BMJ Open20260
Real-world evidence on dupilumab dose spacing and tolerability in children with atopic dermatitis.
PMID 42904793 — skin, dermatitis, skin diseases, child, dermatitis, atopic		Eur J Dermatol20260
A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial.
PMID 42728529 — vitamin d, dermatitis, vitamins, phototherapy, genes, tat, therapeutics, dermatitis, atopic		Dermatol Ther (Heidelb)20260
Injection-related Pain and the Benefit of a Syringe Pump for Dupilumab Adherence in Children with Atopic Dermatitis: a Retrospective Cross-sectional Study.
PMID 42658203 — injections, sexually transmitted diseases, cross-sectional studies, dermatitis, pain, syringes, dermatology, child, dermatitis, atopic		Acta Derm Venereol20260
Real-world Clinical Effectiveness of Guselkumab and Its Impact on Quality of Life and Sexual Quality of Life in Patients with Genital Psoriasis: Results from the CASSIOPEE Study.
PMID 42478139 — quality of life, syphilis, psoriasis, dermatology		Br J Dermatol20260

Clinical Studies 41

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 3 22
N/A 11
Phase 2 7
Phase 4 1

By status:

Completed 20
Recruiting 11
Active not recruiting 6
Unknown 2
Not yet recruiting 1
Terminated 1

By type:

Interventional 33
Observational 8

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 3
multicentricup10 30

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to evaluate the long term safety tolerability and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00 — safety, hidradenitis suppurativa, hidradenitis		Phase 3Active not recruiting2025
A clinical trial to learn more about the effects of GIA632 in people with the most common type of vitiligo
2025-522301-37-00 — safety, vitiligo		Phase 2Recruiting2026
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial
2025-524078-40-00 — urticaria, multiple chronic conditions, therapeutics		Phase 3Recruiting2026
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP PN1)
2024-511879-16-00 — safety, prurigo, therapeutics		Phase 3Active not recruiting2024
Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO)
2023-508879-36-00 — safety, multiple chronic conditions, pruritus, therapeutics		Phase 3Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS